Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Carlos Augusto Monteiro, the epidemiologist who created the concept of "ultra-processed" foods, has questioned an initiative ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

European shares were down sharply on Monday, giving up early gains as worries over erratic US tariffs policies dented sentiment.

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

European shares were down sharply on Monday, giving up early gains as worries over a possible US recession mounted in the wake of the February jobs report published the day before.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative ...

South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over their insulin pen market practices, amid growing concerns about ...